Literature DB >> 9048588

Retinoic acids increase 17 beta-hydroxysteroid dehydrogenase type 1 expression in JEG-3 and T47D cells, but the stimulation is potentiated by epidermal growth factor, 12-O-tetradecanoylphorbol-13-acetate, and cyclic adenosine 3',5'-monophosphate only in JEG-3 cells.

Y S Piao1, H Peltoketo, A Jouppila, R Vihko.   

Abstract

Human 17 beta-hydroxysteroid dehydrogenase type 1 (17HSD type 1) primarily catalyzes the reduction of low activity estrone to high activity estradiol in ovarian granulosa cells and placental trophoblasts 17HSD type 1 is also present in certain peripheral tissues, such as breast tissue. In the present study we investigated the effects of retinoic acids (RAs) together with other stimuli known to modulate estradiol production and/or cell growth on expression of 17HSD type 1 in JEG-3 choriocarcinoma cells and estrogen-responsive T47D breast cancer cells. Treatment of cultured JEG-3 and T47D cells with all-trans-RA and 9-cis-RA increased reductive 17HSD activity and 17HSD type 1 messenger RNA expression severalfold in both cell lines. On the other hand, epidermal growth factor (EGF), Ca ionophore, the protein kinase C activator 12-O-tetradecanoylphorbol-13-acetate (TPA), and cAMP elevated 17HSD type 1 expression only in JEG-3 cells. Correspondingly, the effects of RAs were potentiated by EGF, TPA, and cAMP in JEG-3 cells, whereas no such phenomenon was observed in T47D cells. In JEG-3 cells, simultaneous administration of RAs with TPA and EGF maximally resulted in approximately 40- and 20-fold increases in 17HSD type 1 messenger RNA expression, respectively. The present data indicate that RAs may stimulate estradiol biosynthesis by regulating 17HSD type 1 expression in certain breast cancer and choriocarcinoma cells. The results suggest that interaction of multiple regulatory pathways is involved in maintaining high 17HSD type 1 expression in the placenta. In addition, regulation of 17HSD type 1 expression may be different in trophoblast cells from that in breast epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048588     DOI: 10.1210/endo.138.3.5008

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

Review 2.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

3.  Conversion of Estrone to 17β-Estradiol: A Potential Confounding Factor in Assessing Risks of Environmental Estrogens to Fish.

Authors:  Mark A Tapper; Richard C Kolanczyk; Carlie A LaLone; Jeffrey S Denny; Gerald T Ankley
Journal:  Environ Toxicol Chem       Date:  2020-09-01       Impact factor: 4.218

4.  In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds.

Authors:  I A Meerts; R J Letcher; S Hoving; G Marsh; A Bergman; J G Lemmen; B van der Burg; A Brouwer
Journal:  Environ Health Perspect       Date:  2001-04       Impact factor: 9.031

Review 5.  Gender, sex hormones and pulmonary hypertension.

Authors:  Eric D Austin; Tim Lahm; James West; Stevan P Tofovic; Anne Katrine Johansen; Margaret R Maclean; Abdallah Alzoubi; Masahiko Oka
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.